A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...

Including patients who used topical rescue medication, almost half of patients treated with rocatinlimab met the 75% response criteria compared with 16% of placebo-treated patients. Additionally, a ...

32.8% of rocatinlimab-treated patients achieved the co-primary endpoint of EASI 75 by week 24. 19.3% reached the other co-primary endpoint, defined as a validated IGA-AD score of 0 or 1 by week 24.

The IGNITE study, which evaluated two dose strengths of rocatinlimab, met its co-primary endpoints and all key secondary endpoints, achieving statistical significance for both rocatinlimab dose ...

The data drops provide more evidence that the Kyowa Kirin-partnered rocatinlimab improves outcomes in atopic dermatitis, but questions about the positioning of the anti-OX40 antibody versus Sanofi ...

Ongoing Studies are Evaluating Long-Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE ...

Including patients who used topical rescue medication, almost half of patients treated with rocatinlimab met the 75% response criteria compared with 16% of placebo-treated patients. Additionally ...

THOUSAND OAKS, Calif. and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 ...